Bristol Myers expects to report registrational data in 2026 for six candidates, with key programs including milvexian for atrial fibrillation and secondary stroke prevention, admilparant for idiopathic pulmonary fibrosis, and iberdomide for relapsed or refractory multiple myeloma1
The company reported positive interim phase III results from the SUCCESSOR-2 study for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, marking the first positive phase III study for mezigdomide1
Bristol Myers has undergone a 2023-2024 M&A wave acquiring neuroscience, radiopharma, and precision oncology assets to offset patent losses from generic competition on legacy drugs like Revlimid and support pipeline renewal2
Analysts expect the 2026-2028 period to show improving growth as new launches and acquired pipelines contribute to recovery, with consensus forecasting sequential revenue growth resuming by 20262
The company sustained annual R&D spending near $10 billion to support its diversified late-stage pipeline across oncology, hematology, cardiology, and neuroscience2
Sources:
1. https://www.zacks.com/stock/news/2883253/is-bristol-myers-deep-pipeline-the-key-to-future-growth